ABSTRACT
Innovation through partnerships We have witnessed extraordinary breakthroughs in medicine over the past century; however, the battles to ward off diseases, disorders, and the ailments that come with aging are not yet over. Stunning successes within the industry have led to the public’s high expectations for new and even better and safer medicines at low cost. The pharmaceutical industry is tasked with developing innovative medicines while addressing the pressures of rising costs, increased stringency in drug development processes and regulatory approval, and the changing landscape of drug reimbursement. To mitigate some of these risks, companies within the
Innovation through partnerships .................................................................. 13 Traditional partnering in the biopharmaceutical industry ........................ 15
License agreements ..................................................................................... 16 Collaboration or codevelopment/ cocommercialization partnerships .... 17 Mergers and acquisitions (M&A) .............................................................. 18 Contribution of partnering to date ........................................................... 18
Innovative partnerships of the future ........................................................... 19 Industry-wide collaboration or the megacollaboration ......................... 19 Increased collaboration between diagnostic and therapeutic companies ..................................................................................................... 21 Partnering with academic institutions ..................................................... 23 Innovative collaborations with government research institutes .......... 25
Collaborating with research and development groups to promote innovation ......................................................................................................... 26
Security to innovate .................................................................................... 26 Greater collaboration across the research and development (R&D) organization ..................................................................................... 27 Time for innovation ..................................................................................... 29
Collaborating with the public ........................................................................ 30 Conclusion ........................................................................................................ 32
industry have been and will continue to be active in forging creative and productive business relationships to bring new drugs to market.
